GlassScriptPhysician profile
Ralph Leo Aquadro
NPI 1396797288
$9,275.41
in general payments reported to CMS, 2019-2025
32 companies · $998 in 2025
The $998 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,624 · 2020: $1,778 · 2021: $1,562 · 2022: $1,342 · 2023: $955 · 2024: $1,017 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,949.68 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,372.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $883.41 | 2019-2024 | |
| Lilly USA, LLC | $785.24 | 2019-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $784.56 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.43 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $408.21 | 2021-2025 | |
| Abbvie INC. | $406.28 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $343.87 | 2019-2025 | Evenity, Otezla, Repatha |
| Amarin Pharma, INC. | $288.69 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $231.72 | 2019-2022 | |
| Exact Sciences Corporation | $218.06 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $191.09 | 2023-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $162.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.45 | 2019-2025 | Capvaxive |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $110.13 | 2024-2025 | Daxxify |
| Biohaven Pharmaceutical Holding Company LTD. | $98.37 | 2022 | |
| Esperion Therapeutics, INC. | $84.44 | 2020-2024 | Nexletol |
| Bausch Health US, LLC | $79.91 | 2023-2025 | Wellbutrin, Aplenzin |
| Kowa Pharmaceuticals America, INC. | $54.33 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.39 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $30.34 | 2021 | |
| Vivus LLC | $23.54 | 2022 | |
| Corcept Therapeutics | $22.81 | 2025 | Korlym |
| Biogen, INC. | $21.74 | 2024 | Skyclarys |
| Kyowa Kirin, INC. | $20.09 | 2024 | Crysvita |
| Inspire Medical Systems, INC. | $18.09 | 2025 | Inspire |
| Mentor Worldwide LLC | $18.08 | 2023 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer |
| Novartis Pharmaceuticals Corporation | $17.78 | 2019 | |
| Horizon Therapeutics Plc | $16.22 | 2022 | |
| Sumitomo Pharma America, INC. | $16.17 | 2024 | Gemtesa |
| Allergan, INC. | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Aquadro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.